Showing 1374 results
-
Press release /Real-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS)…
-
Story /An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.
-
Press release /With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the…
-
Story /This moving personal story about the challenges of living with a rare disease is written by Rocco Falchetto, a biochemist and director of analytical sciences and imaging at the Novartis Institutes for BioMedical Research (NIBR).
-
Press release /In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the >…
-
Press release /Includes Initial Data from SMA Type 1 Pivotal Trial (STR1VE) and 24-Month Follow-Up Data from Phase 1 Trial CHICAGO, April 19, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a…
-
Ad hoc release /SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1],[2…
-
Press release /Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in…
-
Press release /LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…